Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amsterdam Molecular Therapeutics, a developer of human gene therapy, has announced that Ronald Lorijn will for personal reasons retire as CEO, effective February 1, 2009.
Subscribe to our email newsletter
Sander Deventer, Amsterdam Molecular Therapeutics’s (AMT) chief scientific officer and co-founder of the company, has been named CEO on an interim basis.
The company has said that the supervisory board will begin a search for a new CEO immediately.
Ferdinand Verdonck, chairman of the supervisory board at AMT, said: “Under Ronald’s leadership the company has delivered outstanding results for which we are very grateful. We look forward to continuing the execution of the company strategy by building on this strong foundation.”